Published in J Inorg Biochem on February 26, 2011
Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med (2001) 11.92
Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer (2009) 5.06
Current status of cadmium as an environmental health problem. Toxicol Appl Pharmacol (2009) 4.85
DNA topoisomerase II and its growing repertoire of biological functions. Nat Rev Cancer (2009) 3.05
Tumor cell death induced by topoisomerase-targeting drugs. Annu Rev Pharmacol Toxicol (2001) 2.97
The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing. Nucleic Acids Res (2008) 2.64
Cadmium: cellular effects, modifications of biomolecules, modulation of DNA repair and genotoxic consequences (a review). Biochimie (2006) 2.23
Secondary leukemias induced by topoisomerase-targeted drugs. Biochim Biophys Acta (1998) 2.17
Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog Nucleic Acid Res Mol Biol (2000) 2.13
Role of oxidative stress in cadmium toxicity and carcinogenesis. Toxicol Appl Pharmacol (2009) 1.81
Mechanisms of cadmium carcinogenesis. Toxicol Appl Pharmacol (2009) 1.66
Glutathione, a first line of defense against cadmium toxicity. FASEB J (1987) 1.44
1,4-Benzoquinone is a topoisomerase II poison. Biochemistry (2004) 1.21
DNA repair systems as targets of cadmium toxicity. Toxicol Appl Pharmacol (2006) 1.21
DNA damage-mediated apoptosis induced by selenium compounds. J Biol Chem (2003) 1.15
Biochemical and proteomics approaches to characterize topoisomerase IIalpha cysteines and DNA as targets responsible for cisplatin-induced inhibition of topoisomerase IIalpha. Mol Pharmacol (2004) 1.07
Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells. Br J Cancer (1994) 1.07
Kinamycins A and C, bacterial metabolites that contain an unusual diazo group, as potential new anticancer agents: antiproliferative and cell cycle effects. Anticancer Drugs (2006) 1.04
Topoisomerase II-mediated cleavage of plasmid DNA. Methods Mol Biol (2001) 1.02
Maleimide is a potent inhibitor of topoisomerase II in vitro and in vivo: a new mode of catalytic inhibition. Mol Pharmacol (2002) 0.97
Collateral sensitivity to the bisdioxopiperazine dexrazoxane (ICRF-187) in etoposide (VP-16)-resistant human leukemia K562 cells. Biochem Pharmacol (1996) 0.97
Mechanism of the cytotoxicity of the diazoparaquinone antitumor antibiotic kinamycin F. Free Radic Biol Med (2007) 0.96
Dietary flavonoids induce MLL translocations in primary human CD34+ cells. Carcinogenesis (2007) 0.93
Metal binding to ligands: cadmium complexes with glutathione revisited. Anal Biochem (2007) 0.93
A structure-based 3D-QSAR study of anthrapyrazole analogues of the anticancer agents losoxantrone and piroxantrone. J Chem Inf Model (2006) 0.91
Perspectives on cadmium toxicity research. Tohoku J Exp Med (2002) 0.89
Structure-activity study of the interaction of bioreductive benzoquinone alkylating agents with DNA topoisomerase II. Cancer Chemother Pharmacol (2005) 0.87
Design, synthesis and biological evaluation of a novel series of anthrapyrazoles linked with netropsin-like oligopyrrole carboxamides as anticancer agents. Bioorg Med Chem (2010) 0.87
The ortho-quinone metabolite of the anticancer drug etoposide (VP-16) is a potent inhibitor of the topoisomerase II/DNA cleavable complex. Mol Pharmacol (1998) 0.86
Thiol-modulated mechanisms of the cytotoxicity of thimerosal and inhibition of DNA topoisomerase II alpha. Chem Res Toxicol (2008) 0.82
The structure-based design, synthesis, and biological evaluation of DNA-binding amide linked bisintercalating bisanthrapyrazole anticancer compounds. Bioorg Med Chem (2009) 0.82
Isothermal titration calorimetry reveals a zinc ion as an atomic switch in the diadenosine polyphosphates. J Biol Chem (2001) 0.80
Nuclear magnetic resonance studies of the solution chemistry of metal complexes. 26. Mixed ligand complexes of cadmium, nitrilotriacetic acid, glutathione, and related ligands. J Inorg Biochem (1990) 0.80
Cadmium uptake by Caco-2 cells: effects of Cd complexation by chloride, glutathione, and phytochelatins. Toxicol Appl Pharmacol (2001) 0.79
The dioxopiperazine derivatives, their leukemogenic potential and other biological effects. Leuk Res (1992) 0.77
Acrylamide catalytically inhibits topoisomerase II in V79 cells. Toxicol In Vitro (2009) 0.77
Expression of a stress-induced hemoglobin affects NO levels produced by alfalfa root cultures under hypoxic stress. Plant J (2003) 1.49
Lipid antioxidant, etoposide, inhibits phosphatidylserine externalization and macrophage clearance of apoptotic cells by preventing phosphatidylserine oxidation. J Biol Chem (2003) 1.12
Class-1 hemoglobins, nitrate and NO levels in anoxic maize cell-suspension cultures. Planta (2004) 1.08
Biochemical and proteomics approaches to characterize topoisomerase IIalpha cysteines and DNA as targets responsible for cisplatin-induced inhibition of topoisomerase IIalpha. Mol Pharmacol (2004) 1.07
Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy. Toxicology (2008) 1.07
Kinamycins A and C, bacterial metabolites that contain an unusual diazo group, as potential new anticancer agents: antiproliferative and cell cycle effects. Anticancer Drugs (2006) 1.04
Arrest of B16 melanoma cells in the mouse pulmonary microcirculation induces endothelial nitric oxide synthase-dependent nitric oxide release that is cytotoxic to the tumor cells. Am J Pathol (2003) 1.01
Mechanisms of cardiolipin oxidation by cytochrome c: relevance to pro- and antiapoptotic functions of etoposide. Mol Pharmacol (2006) 1.00
Mechanism of the cytotoxicity of the diazoparaquinone antitumor antibiotic kinamycin F. Free Radic Biol Med (2007) 0.96
A three-dimensional quantitative structure-activity analysis of a new class of bisphenol topoisomerase IIalpha inhibitors. Mol Pharmacol (2007) 0.92
A structure-based 3D-QSAR study of anthrapyrazole analogues of the anticancer agents losoxantrone and piroxantrone. J Chem Inf Model (2006) 0.91
Cell lysis with dimethyl sulphoxide produces stable homogeneous solutions in the dichlorofluorescein oxidative stress assay. Free Radic Res (2008) 0.90
Toxicity issues in cancer drug development. Curr Opin Investig Drugs (2010) 0.89
Deferiprone protects against doxorubicin-induced myocyte cytotoxicity. Free Radic Biol Med (2002) 0.88
Development of a nitric oxide-releasing analogue of the muscle relaxant guaifenesin for skeletal muscle satellite cell myogenesis. Mol Pharm (2009) 0.88
Myeloperoxidase-catalyzed metabolism of etoposide to its quinone and glutathione adduct forms in HL60 cells. Chem Res Toxicol (2006) 0.88
Structure-activity study of the interaction of bioreductive benzoquinone alkylating agents with DNA topoisomerase II. Cancer Chemother Pharmacol (2005) 0.87
The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II. Biochem Pharmacol (2012) 0.87
Design, synthesis and biological evaluation of a novel series of anthrapyrazoles linked with netropsin-like oligopyrrole carboxamides as anticancer agents. Bioorg Med Chem (2010) 0.87
Kinamycin F downregulates cyclin D3 in human leukemia K562 cells. Chem Biol Interact (2010) 0.85
Potent cytotoxic arylnaphthalene lignan lactones from Phyllanthus poilanei. J Nat Prod (2014) 0.85
c-Abl kinase regulates curcumin-induced cell death through activation of c-Jun N-terminal kinase. Mol Pharmacol (2006) 0.84
A diazirine-based photoaffinity etoposide probe for labeling topoisomerase II. Bioorg Med Chem (2009) 0.83
The mismatch repair system modulates curcumin sensitivity through induction of DNA strand breaks and activation of G2-M checkpoint. Mol Cancer Ther (2010) 0.83
Design, synthesis, and biological evaluation of a novel series of bisintercalating DNA-binding piperazine-linked bisanthrapyrazole compounds as anticancer agents. Bioorg Med Chem (2011) 0.82
Thiol-modulated mechanisms of the cytotoxicity of thimerosal and inhibition of DNA topoisomerase II alpha. Chem Res Toxicol (2008) 0.82
The structure-based design, synthesis and biological evaluation of DNA-binding bisintercalating bisanthrapyrazole anticancer compounds. Bioorg Med Chem (2008) 0.82
The structure-based design, synthesis, and biological evaluation of DNA-binding amide linked bisintercalating bisanthrapyrazole anticancer compounds. Bioorg Med Chem (2009) 0.82
Evaluation of relative DNA binding affinities of anthrapyrazoles by electrospray ionization mass spectrometry. J Mass Spectrom (2007) 0.81
A three-dimensional quantitative structure-activity relationship study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase IIalpha by substituted purine analogs. Mol Pharmacol (2006) 0.81
Myeloperoxidase-dependent oxidation of etoposide in human myeloid progenitor CD34+ cells. Mol Pharmacol (2010) 0.80
The anticancer thiosemicarbazones Dp44mT and triapine lack inhibitory effects as catalytic inhibitors or poisons of DNA topoisomerase IIα. Biochem Pharmacol (2012) 0.79
The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species. Anticancer Drugs (2005) 0.79
Role of NADPH cytochrome P450 reductase in activation of RH1. Cancer Chemother Pharmacol (2007) 0.79
Total synthesis of isoprekinamycin: structural evidence for enhanced diazonium ion character and growth inhibitory activity toward cancer cells. Org Lett (2007) 0.79
Dihydroorotase catalyzes the ring opening of the hydrolysis intermediates of the cardioprotective drug dexrazoxane (ICRF-187). Drug Metab Dispos (2002) 0.78
The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925. Cancer Chemother Pharmacol (2002) 0.78
The dihydroorotase inhibitor 5-aminoorotic acid inhibits the metabolism in the rat of the cardioprotective drug dexrazoxane and its one-ring open metabolites. Drug Metab Dispos (2008) 0.77
Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide. Cancer Chemother Pharmacol (2003) 0.77
Metabolism of the one-ring open metabolites of the cardioprotective drug dexrazoxane to its active metal-chelating form in the rat. Drug Metab Dispos (2005) 0.77
Prevention of doxorubicin-induced damage to rat heart myocytes by arginine analog nitric oxide synthase inhibitors and their enantiomers. Nitric Oxide (2003) 0.77
The iron chelating cardioprotective prodrug dexrazoxane does not affect the cell growth inhibitory effects of bleomycin. J Inorg Biochem (2004) 0.76
Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent. Cancer Chemother Pharmacol (2003) 0.76
Molecular mechanisms of the biological activity of the anticancer drug elesclomol and its complexes with Cu(II), Ni(II) and Pt(II). J Inorg Biochem (2013) 0.76
Metabolism of the cardioprotective drug dexrazoxane and one of its metabolites by isolated rat myocytes, hepatocytes, and blood. Drug Metab Dispos (2005) 0.75
Chemical reactivity and microbicidal action of bethoxazin. Bioorg Med Chem (2012) 0.75
Anti-/pro-oxidant effects of phenolic compounds in cells: are colchicine metabolites chain-breaking antioxidants? Toxicology (2002) 0.75
Structure-activity studies with cytotoxic anthrapyrazoles. Oncol Rep (2006) 0.75